 | • レポートコード：MRC2303J0209 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、236ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートによると、2021年に205.9億ドルであった世界の動物用医薬品市場規模は、2022年に217.6億ドルになり、2027年までにCAGR 5.88％で拡大して290.1億ドルに達するとみられています。本書は、動物用医薬品の世界市場を対象とした調査結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬剤種類別（抗感染症薬、抗炎症薬、寄生虫駆除剤）分析、投与経路別（経口薬、非経口薬、局所薬）分析、動物種類別（伴侶動物、家畜動物）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、下記の項目を掲載しています。なお、本書内の企業情報としては、Bayer AG、Bimeda, Inc.、Biogenesis Bago SA、Boehringer Ingelheim GmbH、Century Pharmaceuticals Limited、Ceva Sante Animale SA、Dechra Pharmaceuticals PLC、Elanco Animal Health Incorporated、Hester Biosciences Limitedなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の動物用医薬品市場規模：薬剤種類別 - 抗感染症薬の市場規模 - 抗炎症薬の市場規模 - 寄生虫駆除剤の市場規模 ・世界の動物用医薬品市場規模：投与経路別 - 経口薬の市場規模 - 非経口薬の市場規模 - 局所薬の市場規模 ・世界の動物用医薬品市場規模：動物種類別 - 伴侶動物における市場規模 - 家畜動物における市場規模 ・世界の動物用医薬品市場規模：地域別 - 南北アメリカの動物用医薬品市場規模 アメリカの動物用医薬品市場規模 カナダの動物用医薬品市場規模 ブラジルの動物用医薬品市場規模 ... - アジア太平洋の動物用医薬品市場規模 日本の動物用医薬品市場規模 中国の動物用医薬品市場規模 インドの動物用医薬品市場規模 韓国の動物用医薬品市場規模 台湾の動物用医薬品市場規模 ... - ヨーロッパ/中東/アフリカの動物用医薬品市場規模 イギリスの動物用医薬品市場規模 ドイツの動物用医薬品市場規模 フランスの動物用医薬品市場規模 ロシアの動物用医薬品市場規模 ... - その他地域の動物用医薬品市場規模 ・競争状況 ・企業情報 |
The Global Veterinary Drug Market size was estimated at USD 20.59 billion in 2021 and expected to reach USD 21.76 billion in 2022, and is projected to grow at a CAGR 5.88% to reach USD 29.01 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Veterinary Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Type, the market was studied across Anti-Infective, Anti-Inflammatory, and Parasiticide.
Based on Route of Administration, the market was studied across Oral, Parenteral, and Topical.
Based on Animal Type, the market was studied across Companion Animal and Livestock Animal.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Veterinary Drug market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Veterinary Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Veterinary Drug Market, including Bayer AG, Bimeda, Inc., Biogenesis Bago SA, Boehringer Ingelheim GmbH, Century Pharmaceuticals Limited, Ceva Sante Animale SA, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Hester Biosciences Limited, Indian Immunologicals Ltd., Jurox Pty Ltd, Kindred Biosciences, Inc., Kyoritsu Seiyaku Corporation, Merck & Co., Inc., Neogen Corporation, Novartis AG, Pharmgate LLC, Phibro Animal Health Corporation, Vetoquinol SA, Virbac SA, and Zoetis Inc.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Veterinary Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Veterinary Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Veterinary Drug Market?
4. What is the competitive strategic window for opportunities in the Global Veterinary Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Veterinary Drug Market?
6. What is the market share of the leading vendors in the Global Veterinary Drug Market?
7. What modes and strategic moves are considered suitable for entering the Global Veterinary Drug Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising demand for animals and animal-derived products
5.1.1.2. Increasing animal ownership have increased usage of veterinary drugs
5.1.1.3. Growing penetration of pet insurance
5.1.1.4. Growing availability of numerous veterinary drugs for treatment of several diseases
5.1.2. Restraints
5.1.2.1. Lack of veterinary infrastructure facilities
5.1.3. Opportunities
5.1.3.1. Introduction of new and advanced veterinary drugs
5.1.3.2. Emergence of easy-to-give drugs such as oral liquid solutions
5.1.3.3. Expansion of animal healthcare expenditure
5.1.3.4. Growth in the clinical animal researches to treat various diseases
5.1.4. Challenges
5.1.4.1. High pet care cost
5.2. Cumulative Impact of COVID-19
6. Veterinary Drug Market, by Drug Type
6.1. Introduction
6.2. Anti-Infective
6.3. Anti-Inflammatory
6.4. Parasiticide
7. Veterinary Drug Market, by Route of Administration
7.1. Introduction
7.2. Oral
7.3. Parenteral
7.4. Topical
8. Veterinary Drug Market, by Animal Type
8.1. Introduction
8.2. Companion Animal
8.3. Livestock Animal
9. Americas Veterinary Drug Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Veterinary Drug Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Veterinary Drug Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Bayer AG
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Bimeda, Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Biogenesis Bago SA
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Boehringer Ingelheim GmbH
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Century Pharmaceuticals Limited
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Ceva Sante Animale SA
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Dechra Pharmaceuticals PLC
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Elanco Animal Health Incorporated
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Hester Biosciences Limited
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Indian Immunologicals Ltd.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Jurox Pty Ltd
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Kindred Biosciences, Inc.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Kyoritsu Seiyaku Corporation
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Merck & Co., Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Neogen Corporation
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Novartis AG
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Pharmgate LLC
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Phibro Animal Health Corporation
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Vetoquinol SA
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Virbac SA
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Zoetis Inc
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing